ROCK & ASSOCIATES for DIAMONDBACK DRUGS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Budget/Appropriations BUD
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Pharmacy PHA
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.